On the other hand, AMPK can inhibit DNA demethylation of the SREBP-1 promoter mediated by TDG, suggesting that TDG regulated by insulin or metformin is a potential therapeutic target for T2DM-related cancers (54). The gene discussed is SREBF1; the disease is cancer.